The DOI matches its Crossref record.
Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma
Open accessAbstract
The actual impact of transarterial chemoembolization before liver transplantation (LT) for hepatocellular carcinoma (HCC) on patient survival and HCC recurrence is not known. Between 1985 and 1998, 479 patients with HCC in 14 French centers were evaluated for LT. Among these 479 patients, this case-control study included 100 patients who received transarterial chemoembolization before LT (TACE group) and 100 control patients who did not receive chemoembolization (no-TACE group). Patients and controls were matched for the pre-LT tumor characteristics, the period of transplantation, the time spent on the waiting list, and pre- and posttransplantation treatments. Kaplan-Meier estimates were calculated 5 years after LT and were compared with the log-rank test. The mean waiting time before LT was 4.2 +/- 3.2 months in the TACE group and 4.3 +/- 4.4 months in the no-TACE group. The median number of TACE procedures was 1 (range: 1-12). Demographic data, median alpha-fetoprotein level (21.6 ng/mL and 22.0 ng/mL, respectively), and pre- and post-LT morphologic characteristics of the tumors did not differ in the TACE and no-TACE groups. Overall 5-year survival was 59.4% with TACE and 59.3% without TACE (ns). Survival rates did not differ significantly between the two groups with respect to the time on the waiting list, the tumor diameter, or the type of TACE (selective or nonselective). In the TACE group, 30 patients had tumor necrosis > or =80% on the liver explant with a 5-year survival rate of 63.2%, compared with 54.2% among their matched controls (P = 0.9). In conclusion, with a mean waiting period of 4.2 months and 1 TACE procedure, pre-LT TACE does not influence post-LT overall survival and disease-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Since the publication of the seminal study [226], case– control studies including index treated cases and matched controls indicate similar survival rates as untreated individuals [227,228].”
ResultEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Duvoux, C., Roudot–Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T., Francoz, C., Compagnon, P., Vanlemmens, C., Dumortier, J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.052 · Cited by 955
Self-citationNovel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Otto, G., Herber, S., Heise, M., Lohse, A. W., Mönch, C., Bittinger, F., Hoppe-Lotichius, M., Schuchmann, M., Victor, A., & Pitton, M. (2006) · Liver Transplantation · doi:10.1002/lt.20837 · Cited by 410
Metadata
- Authors
- Decaens, T., Roudot‐Thoraval, F., Bresson‐Hadni, S., Meyer, C., Gugenheim, J., Durand, F., Bernard, P., Boillot, O., Boudjema, K., Calmus, Y., Hardwigsen, J., Ducerf, C., Pageaux, G. P., Dharancy, S., Chazouilleres, O., Dhumeaux, D., Cherqui, D., & Duvoux, C.
- Venue
- Liver Transplantation
- Published
- 2005-06-22
- Volume
- 11
- Issue
- 7
- Pages
- 767-775
- ISSN
- 1527-6465 (ISSN-L)
- 1527-6473
- OpenAlex
- W2059079639
- Cited by
- 222
- References
- 0
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1002/lt.20418
- The paper
- Decaens, T., Roudot‐Thoraval, F., Bresson‐Hadni, S., Meyer, C., Gugenheim, J., Durand, F., Bernard, P., Boillot, O., Boudjema, K., Calmus, Y., Hardwigsen, J., Ducerf, C., Pageaux, G. P., Dharancy, S., Chazouilleres, O., Dhumeaux, D., Cherqui, D., & Duvoux, C. (2005). Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transplantation. https://doi.org/10.1002/lt.20418
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.